NASDAQ:CTNM Contineum Therapeutics (CTNM) Stock Price, News & Analysis $18.50 +0.90 (+5.11%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$17.66▼$18.6250-Day Range$16.00▼$21.7552-Week Range$13.27▼$22.00Volume16,133 shsAverage Volume80,873 shsMarket Capitalization$475.88 millionP/E RatioN/ADividend YieldN/APrice Target$28.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Contineum Therapeutics alerts: Email Address Contineum Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside55.0% Upside$28.67 Price TargetShort InterestBearish8.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.95) to ($1.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.97 out of 5 starsMedical Sector603rd out of 924 stocksPharmaceutical Preparations Industry272nd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingContineum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageContineum Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Contineum Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.11% of the float of Contineum Therapeutics has been sold short.Short Interest Ratio / Days to CoverContineum Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Contineum Therapeutics has recently decreased by 0.50%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldContineum Therapeutics does not currently pay a dividend.Dividend GrowthContineum Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTNM. Previous Next 2.3 News and Social Media Coverage News SentimentContineum Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Contineum Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Contineum Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next N/A Company Ownership Insider Buying vs. Insider SellingIn the past three months, Contineum Therapeutics insiders have not sold or bought any company stock.Read more about Contineum Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Contineum Therapeutics are expected to grow in the coming year, from ($1.95) to ($1.83) per share.Read more about Contineum Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Preserve GoldTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared?Click here to get your complimentary retirement guide! About Contineum Therapeutics Stock (NASDAQ:CTNM)Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Read More CTNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTNM Stock News HeadlinesAugust 18, 2024 | americanbankingnews.comContineum Therapeutics (NASDAQ:CTNM) Shares Up 5.3%August 17, 2024 | americanbankingnews.comRoyal Bank of Canada Boosts Contineum Therapeutics (NASDAQ:CTNM) Price Target to $32.00August 22, 2024 | DTI (Ad)3 dividend stocks to ownThe “Income Ace” Jack Carter just revealed his entire dividend strategy. Including 3 specific tickers to consider owning. And his “golden rules” for trading dividend stocks. These aren’t just theoretical rules, either. Jack revealed that the vast majority of his income capital is deployed in this straightforward portfolio of dividend stocks.August 13, 2024 | markets.businessinsider.comCTNM Stock Earnings: Contineum Therapeutics Misses EPS for Q2 2024June 13, 2024 | seekingalpha.comContineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track ModelMay 21, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)May 20, 2024 | businesswire.comContineum Therapeutics Announces Appointment of Troy Ignelzi to Board of DirectorsMay 16, 2024 | businesswire.comContineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsAugust 22, 2024 | DTI (Ad)3 dividend stocks to ownThe “Income Ace” Jack Carter just revealed his entire dividend strategy. Including 3 specific tickers to consider owning. And his “golden rules” for trading dividend stocks. These aren’t just theoretical rules, either. Jack revealed that the vast majority of his income capital is deployed in this straightforward portfolio of dividend stocks.May 11, 2024 | investing.comContineum Therapeutics Inc (CTNM)May 2, 2024 | finance.yahoo.comContineum Therapeutics Announces Pricing of Initial Public OfferingSee More Headlines Receive CTNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today8/21/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTNM Previous SymbolNASDAQ:CTNM CUSIPN/A CIK1855175 Webwww.contineum-tx.com Phone(858) 333-5280FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$28.67 High Stock Price Target$32.00 Low Stock Price Target$25.00 Potential Upside/Downside+55.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio19.20 Quick Ratio19.20 Sales & Book Value Annual Sales$50 million Price / Sales9.52 Cash Flow$1.18 per share Price / Cash Flow15.67 Book Value($3.72) per share Price / Book-4.97Miscellaneous Outstanding Shares25,723,000Free FloatN/AMarket Cap$475.88 million OptionableN/A BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Carmine N. Stengone MBA (Age 48)MS, President, CEO, Secretary & Director Comp: $790.3kMr. Peter T. Slover CPA (Age 49)Chief Financial Officer Comp: $569.7kDr. Daniel S. Lorrain Ph.D. (Age 55)Chief Science Officer Comp: $565.02kDr. Stephen L. Huhn F.A.A.P (Age 63)F.A.C.S., M.D., Chief Medical Officer & Senior VP of Clinical Development Mr. Austin Chen Ph.D.SVP & Head of ResearchMr. Michael MayberrySenior Director & Corporate ControllerMore ExecutivesKey CompetitorsEdgewise TherapeuticsNASDAQ:EWTXRocket PharmaceuticalsNASDAQ:RCKTAkero TherapeuticsNASDAQ:AKROArvinasNASDAQ:ARVNZai LabNASDAQ:ZLABView All CompetitorsInstitutional OwnershipPerceptive Advisors LLCBought 1,566,668 shares on 8/16/2024Ownership: 6.091%Driehaus Capital Management LLCBought 66,667 shares on 8/16/2024Ownership: 0.259%Squarepoint Ops LLCBought 150,000 shares on 8/14/2024Ownership: 0.583%Sandia Investment Management LPBought 5,000 shares on 8/14/2024Ownership: 0.019%Johnson & JohnsonBought 1,979,173 shares on 8/9/2024Ownership: 7.694%View All Institutional Transactions CTNM Stock Analysis - Frequently Asked Questions How have CTNM shares performed this year? Contineum Therapeutics' stock was trading at $15.40 at the start of the year. Since then, CTNM shares have increased by 20.1% and is now trading at $18.50. View the best growth stocks for 2024 here. How were Contineum Therapeutics' earnings last quarter? Contineum Therapeutics, Inc. (NASDAQ:CTNM) posted its earnings results on Tuesday, August, 13th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02. When did Contineum Therapeutics IPO? Contineum Therapeutics (CTNM) raised $110 million in an IPO on Friday, April 5th 2024. The company issued 6,875,000 shares at a price of $16.00 per share. When does the company's lock-up period expire? Contineum Therapeutics' lock-up period expires on Wednesday, October 2nd. Contineum Therapeutics had issued 6,875,000 shares in its IPO on April 5th. The total size of the offering was $110,000,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period. Who are Contineum Therapeutics' major shareholders? Top institutional investors of Contineum Therapeutics include Johnson & Johnson (7.69%), Perceptive Advisors LLC (6.09%), Versant Venture Management LLC (3.57%) and Squarepoint Ops LLC (0.58%). How do I buy shares of Contineum Therapeutics? Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTNM) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
